Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

January 07, 2019   |   January 2019 Bond Updates
UPPSALA, Sweden, Jan. 7, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from the human pharmacokinetic (PK) study OX124-001 in 20 healthy volunteers, assessing Orexo's novel ...

View more at: https://www.prnewswire.com:443/news-releases/positive-results-from-human-pk-study-assessing-orexos-new-intranasal-naloxone-formulations-for-opioid-overdose-reversal-300773591.html
Related News
Home| About us | Contact us http://www.bondupdatesdailynews.com/